“Global AI In Drug Repurposing Market to reach a market value of USD 4.11 Billion by 2032 growing at a CAGR of 19.7%”
The Global AI In Drug Repurposing Market size is expected to reach $4.11 billion by 2032, rising at a market growth of 19.7% CAGR during the forecast period.
The pharmaceutical sector is experiencing a transformative shift as AI revolutionizes drug repurposing-identifying new therapeutic uses for existing compounds. Drug repurposing has developed into a systematic and data-driven approach powered by deep learning, graph-based models, and machine learning. By deploying vast biomedical datasets-including proteomics, clinical records, and genomics, AI now unveils complex drug-disease relationships that were not evident previously. This development has shifted AI-based repurposing from an experimental idea to a mainstream R&D strategy, supported by a strong partnership between technology providers and pharmaceutical companies. AI allows more efficient lifecycle management, enhanced targeting of unmet medical requirements, and faster drug discovery timelines.
The AI in Drug Repurposing market is anticipated to grow, driven by numerous trends. Repurposing is expanding into rescue programs and rare diseases for previously failed molecules, offering strategic as well as humanitarian advantages. Adaptive learning systems now allow continued model updates as new data emerges, improving long-term value and accuracy. Also, AI systems largely manage multimodal data and focus on explainability, providing mechanistic insights that clinical trust and build regulatory confidence. Market players deploy vertical partnerships, hybrid business models, and scalable AI platforms to support innovation. The market is witnessing intensive competition as the landscape is predicted to consolidate around a few integrated AI bio-ecosystems connected to pharma pipelines, with players emphasizing on rare conditions or specific therapeutic.
The COVID-19 pandemic sped up the use of AI in drug repurposing a lot, showing how important it is for pharmaceutical R&D. Organizations used AI to quickly screen existing compounds because they needed treatments right away. This cut the time it took to find new drugs from years to weeks. AI models were able to make better predictions because there was more data available on SARS-CoV-2. Preliminary success stories also made investors and the industry more confident. Public-private partnerships and collaborative data-sharing projects added to AI datasets, which led to new ideas for hybrid modeling approaches. As a result, AI repurposing went from being a test project to a key part of modern drug development, showing how it could change things even after the pandemic. Thus, the COVID-19 pandemic had a positive impact on the market.
Based on Technology, the market is segmented into Machine Learning/Deep Learning, Natural Language Processing (NLP), Knowledge Graphs & Network-Based AI, Generative AI & Large Language Models (LLMs), and Computer Vision. The natural language processing (NLP) segment witnessed 20% revenue share in the AI In drug repurposing market in 2024. Natural language processing plays a vital role in extracting insights from unstructured biomedical information such as research papers, patents, and clinical trial reports. NLP algorithms can scan millions of documents to identify potential drug–target or drug–disease connections by interpreting scientific language contextually.
Based on End Use, the market is segmented into Pharmaceutical & BioTechnology Companies, Contract Research Organizations (CROs), Academic & Research Institutes, and Other End Use. The contract research organizations (CROs) segment recorded 20% revenue share in the AI In drug repurposing market in 2024. Contract research organizations are increasingly adopting AI-based platforms for drug repurposing to support pharmaceutical clients with data processing, clinical insights, and experimental validation. CROs use AI tools to design efficient trial protocols, identify drug candidates with repurposing potential, and model patient responses.
Free Valuable Insights: AI In Drug Repurposing Market size to reach USD 4.11 Billion by 2032
Region-wise, the AI In Drug Repurposing Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded 42% revenue share in the AI In Drug Repurposing Market in 2024. The AI in Drug Repurposing market is anticipated to grow at a significant rate in North America and Europe. This is due to large investment in pharma R&D, well-established ecosystem of AI startups collaborating CROs and big pharma, and extensive biomedical datasets (real-world evidence, EHRs, and genomics). Furthermore, the European market has strong translational research networks, well-established biotech and pharmaceutical clusters, and growing regulatory interest in AI-based tools, resulting in strong demand. Also, Europe focuses on data privacy deployments and regulatory alignment, which result in surging clinical validation of repurposing candidates.
In the Asia Pacific and LAMEA regions, the AI in Drug Repurposing market is expected to experience substantial expansion. This is driven by rapidly growing R&D spending in India, South Korea, and China, regional health/AI initiatives, rising biomedical data availability, and numerous partnerships between global pharma and regional AI providers. Moreover, the LAMEA region is also witnessing growth due to the rising clinical trial activity and increasing government digital health programs. The global collaborations and private investments target region-specific demands, particularly in nations with strong healthcare infrastructure.
| Report Attribute | Details |
|---|---|
| Market size value in 2025 | USD 1.16 Billion |
| Market size forecast in 2032 | USD 4.11 Billion |
| Base Year | 2024 |
| Historical Period | 2021 to 2023 |
| Forecast Period | 2025 to 2032 |
| Revenue Growth Rate | CAGR of 19.7% from 2025 to 2032 |
| Number of Pages | 600 |
| Number of Tables | 491 |
| Report coverage | Market Trends, Revenue Estimation and Forecast, Segmentation Analysis, Regional and Country Breakdown, Porter’s 5 Forces Analysis, Company Profiling, Companies Strategic Developments, SWOT Analysis, Winning Imperatives |
| Segments covered | Component, Technology, End Use, Application, Region |
| Country scope |
|
| Companies Included | Ginkgo Bioworks Holdings, Inc., IBM Corporation, Atomwise, Inc., Cyclica, Inc., Genesis Healthcare Co., Verge, Inc., Novartis AG, Schrödinger, Inc, Recursion Pharmaceuticals, Inc., and The Cradle Company |
By Component
By Technology
By End Use
By Application
By Geography
This Market size is expected to reach USD 4.11 billion by 2032.
The AI in drug repurposing market is projected to grow at a CAGR of 19.7% between 2025 and 2032.
Pressure to reduce cost, risk, and duration of drug development is accelerated by rapid advances in artificial intelligence and computational infrastructure.
Ginkgo Bioworks Holdings, Inc., IBM Corporation, Atomwise, Inc., Cyclica, Inc., Genesis Healthcare Co., Verge, Inc., Novartis AG, Schrödinger, Inc, Recursion Pharmaceuticals, Inc., and The Cradle Company.
The Software & Platform segment captured the maximum revenue in the Global AI In Drug Repurposing Market by Component in 2024, thereby, achieving a market value of $2.6 billion by 2032.
The North America region dominated the Global AI In Drug Repurposing Market by Region in 2024, and would continue to be a dominant market till 2032; thereby, achieving a market value of $1.7 billion by 2032.
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 